Method and product for blood treatment and purification
Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment.
1. A method for blood treatment or purification, comprising
separating blood cells from plasma in a first filter or a first centrifuge,
transporting the separated plasma onwards in a plasma conduit and mixing the separated plasma with a suspension containing at least one component specifically binding a target substance that is to be reduced in the blood such that the mixture of the component and separated plasma is transported together toward a second filter or a second centrifuge,
separating both the component and the component having the target substance bound thereto from the plasma in the second filter or the second centrifuge, wherein the plasma having a reduced content of target substance passes through pores of the second filter or a separating element of the second centrifuge,
the separated component and/or the separated component having the target substance bound thereto
a) are returned to the plasma,
b) are transported to a waste bag, or
c) are collected for refining the target substance from the component by elution,
the component comprises a non-soluble polymer matrix and at least one covalently bound ligand,
the target substance is an antibody, a protein, a virus, bacteria, or a cell, and
recirculating the plasma having a reduced content of the target substance to the blood cells, wherein purified blood is obtained.
2. The method according to claim 1 , wherein the target substance is a blood group specific antibody.
3. The method according to claim 2 , wherein the blood group specific antibody is an anti-A, an anti-A and anti-B, or an anti-B antibody.
4. The method according to claim 1 , wherein the target substance is an antibody active against pathogenic bacteria or viruses.
5. The method according to claim 1 , wherein the ligand is a saccharide, a protein or an antibody.
6. The method according to claim 5 , wherein the saccharide is a mono-, di-, tri-, tetra-, penta- or higher oligosaccharide or a oligosaccharide derivative.
7. The method according to claim 5 , wherein the saccharide contains one of or a combination of at least two of the blood group sequences for blood group A, one of or a combination of at least two of the blood group sequences for blood group B, or one of or a combination of at least two of the blood group sequences for blood group H.
8. The method according to claim 1 , wherein the ligand is provided with a spacer distancing the matrix from the ligand.
9. The method according to claim 1 , wherein the component is added continuously.
10. A method for therapeutic treatment or purification of a patient's blood, wherein blood is extracted from the patient, the blood is treated by the method according to claim 1 , and the purified blood obtained is returned to the patient.
11. The method according to claim 2 , wherein the component is added continuously.
12. The method according to claim 4 , wherein the component is added continuously.
13. The method according to claim 6 , wherein the component is added continuously.
14. The method according to claim 1 , wherein the non-soluble polymer matrix is a plastic or a polysaccharide.
15. The method according to claim 14 , wherein the polysaccharide is a cross-linked agarose.
16. The method according to claim 10 , wherein the non-soluble polymer matrix is a plastic or a polysaccharide.
17. The method of claim 1 , wherein the second filter and the second centrifuge each have an internal upstream feed region and a downstream filtrate region, and the plasma having the reduced content of target substance passes from the upstream feed region to the downstream filtrate region.
18. The method of claim 17 , wherein the second filter and the second centrifuge each have a downstream pass through region that allows passage of the component and the component having the target substance bound thereto.
19. The method of claim 1 , wherein the non-soluble polymer matrix is about 1 μm to about 300 μm in particle size.
20. A method for blood treatment or purification, comprising
separating blood cells from plasma in a first filter or a first centrifuge,
transporting the separated plasma onwards in a plasma conduit and mixing the separated plasma with a suspension containing at least one component specifically binding a target substance that is to be reduced in the blood such that the mixture of the component and separated plasma is transported together toward a second filter downstream of the first filter or first centrifuge,
separating both the component and the component having the target substance bound thereto from the plasma in the second filter downstream of the first filter or first centrifuge, wherein the second filter is porous and the plasma having a reduced content of target substance passes through pores of the second filter,
the separated component, and/or the separated component having the target substance bound thereto
a) are returned to the plasma,
b) are transported to a waste bag, or
c) are collected for refining the target substance from the component by elution,
the component comprises a non-soluble polymer matrix and at least one covalently bound ligand,
the target substance is an antibody, a protein, a virus, bacteria, or a cell, and
recirculating the plasma having the reduced content of the target substance to the blood cells, wherein purified blood is obtained.
21. The method of claim 20 , wherein the second filter has a pore size that is sized as to allow for complete passage of the plasma having the reduced content of target substance.
22. A method for blood treatment or purification, comprising
separating blood cells from plasma in a first filter or a first centrifuge,
transporting the separated plasma onwards in a plasma conduit and mixing the separated plasma with a suspension containing at least one component specifically binding a target substance that is to be reduced in the blood such that the mixture of the component and separated plasma is transported together toward a second filter downstream of the first filter or first centrifuge,
separating both the component and the component having the target substance bound thereto from the plasma in the second filter downstream of the first filter or first centrifuge, wherein the second filter is porous and the component and the component having the target substance bound thereto do not pass through pores of the second filter,
the separated component and/or the separated component having the target substance bound thereto
a) are returned to the plasma,
b) are transported to a waste bag, or
c) are collected for refining the target substance from the component by elution,
the component comprises a non-soluble polymer matrix and at least one covalently bound ligand,
the target substance is an antibody, a protein, a virus, bacteria, or a cell, and
recirculating the plasma having the reduced content of the target substance to the blood cells, wherein purified blood is obtained.
23. The method of claim 1 , wherein the component and the component having the target substance bound thereto, after leaving the second filter or the second centrifuge, are separated and the component without the target substance bound thereto is recirculated for mixing with the separated plasma from the first filter or first centrifuge.
24. The method of claim 1 , wherein the first and second filters are utilized and the first filter is a coarser filter than the second filter.